He received honorary doctorates from Aalborg Silesian and Pécs Universities. He has authored more than 20 books and 180 journal papers, along with 200 conference papers and abstracts and delivered over 200 keynote and plenary talks at respected international conferences, including ICASSP twice.

He is a recipient of the IEEE EMBS Career, Early Career, Distinguished Service and Career Achievement Awards, an IEEE Third Millennium Medal, and the prestigious Zworykin Award from the International Federation for Medical and Biological Engineering (IFMBE). He is a fellow of the Institute of Physics (IOP), the International Academy of Medical and Biological Engineering (IAMBE), the American Institute for Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS).

His research focuses on neurotechnology for addiction and pain, brain cancer chips, and coronary occlusion.

He was previously Deputy President (I&E) at the National University of Singapore from January 2018 to December 2022, Provost (January 2011 – December 2017) and Chair of the School of Materials Science and Engineering (January 2004 – December 2010) at the Nanyang Technological University.

Professor Boey was conferred Singapore’s highest Scientific Award, the President’s Science & Technology Medal for lifetime achievement, and the prestigious Imperial College London Faculty of Medicine Fellow award, both in 2013, for his biomedical research achievements. His research team also won the 2014 Singapore President’s Technology Award for using nanostructures with a novel drug delivery approach to combat blindness from glaucoma. As Provost, he built Singapore’s second Undergraduate Medical School, partnering with Imperial College London, for which he received the 2016 Singapore National Day Public Administration Gold Medal. He has also been conferred Honorary Doctorate from Loughborough University, and Honorary professorships from the University of Indonesia, Nanjing Postal and Telecom University and Nanjing Technological University.   

He emerged as an internationally recognized scientist in the fields of interdisciplinary research of biomechanics & biomaterials. His lab focused on translating biomedical research findings into products and clinical applications that will benefit human health. Dr. Fan has published more than 400 articles and chaired many symposium, conferences and sessions, served on numerous review panels for government and private agencies in China, served as an editor for 5 international journals, and reviewed manuscripts for more than 30 journals.

He was previously Executive Vice President in charge of finance and external relations for the university and took the office of the President on April 1, 2021. He has also served as an Executive Member(part-time) of the Japanese Cabinet Office’s Council for Science, Technology and Innovation from March 2021 until February 2024.

Dr. Fujii received his Ph.D. in engineering from UTokyo in 1993. His research specializes in applied microfluidics systems and underwater technology.

He is recognized for his outstanding contributions in scalable synthesis of uniform nanoparticles, and pioneering research in designed synthesis of inorganic nanomaterials for biomedical, energy, and soft-electronic-device applications. He was listed in Top 100 Chemists in 2011, Highly Cited Researcher (both Chem&MSE) from 2014 to 2023, and chosen as 2020 Citation Laureate in Chemistry. He received four major Korean Sci&Tech awards including 2022 Grand Prize of National Academy of Engineering of Korea, 2016 Presidential Korea’s Best Scientist Award, 2012 Samsung Hoam Prize, and 2008 POSCO-T.J. Park Award. He also received 2016 IUVSTA Prize at International Vacuum Congress, and delivered Kavli Foundation Frontiers of Materials Research Lecture. He is an elected Fellow/Member of Korean Academy of Science and Technology, National Academy of Engineering of Korea, US National Academy of Engineering, Swedish Royal Academy of Engineering Sciences, Royal Society of Chemistry, and Materials Research Society. From 2010 to 2020, he served as Associate Editor of J. Am. Chem. Soc.

The Kelley research group has pioneered new methods for tracking molecular and cellular analytes with unprecedented sensitivity.  Dr. Kelley’s work has been recognized with the ACS Inorganic Nanoscience Award, the Pittsburgh Conference Achievement Award, the Steacie Prize, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and she was also named a “Top 100 Innovator” by MIT’s Technology Review.  Kelley is also a Guggenheim Fellow, a Fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, and the American Institute of Biological and Medical Engineering. She is an elected member of the American Academy of Arts and Sciences and the National Academy of Inventors. Her work is extensively cited and she has over 80 papers cited more than 80 times.  Kelley is an inventor on over 50 patents issued worldwide.  She is a founder of four life sciences companies, GeneOhm Sciences (acquired by Becton Dickinson in 2005), Xagenic Inc. (acquired by General Atomics in 2017), CTRL Therapeutics (founded in 2019) and Arma Biosciences (founded in 2021).  

Formerly, he was a Director of the Physical Intelligence Department at Max Planck Institute for Intelligent Systems in Stuttgart, Germany (2014-2023), Professor at ETH Zurich, Switzerland (2020-2024), and Professor at Carnegie Mellon University (2002-2014) and a research scientist at UC Berkeley (1999-2002) in USA. He received his BSc (1992) and MSc (1994) degrees from Boğaziçi University, Turkey, and PhD degree from University of Tokyo, Japan (1999). His research interests include small-scale mobile robotics, bio-inspiration, wireless medical devices, and physical intelligence. He is a National Academy of Engineering (NAE) Member in USA and an IEEE Fellow. He received the Highly Cited Researcher recognition (2021, 2022, 2023), Breakthrough of the Year Award in the Falling Walls World Science Summit (2020), ERC Advanced Grant (2019), Rahmi Koç Science Medal (2018), SPIE Nanoengineering Pioneer Award (2011), and NSF CAREER Award (2005). He received over 20 best paper, poster and video awards at major conferences. He has supervised and mentored over 70 (21 current) PhD students and over 70 (10 current) postdocs, where over 55 of his group past group members are professors around the world. He has published 2 books and over 400 journal articles and has over 12 issued and 18 pending patents. He founded Setex Technologies Inc. to commercialize his lab’s gecko-inspired microfiber adhesive technology. He is the editor-in-chief of Progress in Biomedical Engineering and Journal of Micro-Bio Robotics journals and associate editor in Science Advances journal.

He then joined the University of California, Davis, initially as a postdoctoral fellow, before becoming a project scientist in the Department of Biomedical Engineering. Currently, Dr. Zheng is an academician at the Chinese Academy of Sciences, serves as vice president of Nanjing University, and professor of the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. His research primarily focuses on medical imaging technology and instrumentation systems, with a particular emphasis on MRI and biomedical ultrasound. Dr. Zheng is the recipient of the National Science Fund for Distinguished Young Scholars and has led several major scientific research projects. Additionally, he holds the position of director at the National Innovation Center for Advanced Medical Devices, and acts as vice president of the Chinese Society of Biomedical Engineering. For his contributions, Dr. Zheng has been honored with the National Science and Technology Award.

He received his PhD (1997) in Mechanical Engineering at Osaka University. He joined the Department of Mechanical Engineering as a Research Associate (1992) and an Associate Professor (1998) at Kobe University, worked as a Research Fellow at the Orthopaedic Research Laboratory at the University of Michigan (1997-99). He joined the Department of Mechanical Engineering as Associate Professor (2004) at Kyoto University, and he is currently Professor (2010-) at the Institute for Life and Medical Sciences. He is working in the fields of bone adaptation, tissue morphogenesis, cell and molecular biomechanics. He served a Member of World Council of Biomechanics (2010-22), and has been a Member of Executive Committee of the Asian-Pacific Association for Biomechanics (2013-).

She received Postdoctoral Fellowship in Laser Medicine from the Massachusetts General Hospital in US. Prof. Chan served the Biomedical Engineering programme of the University of Hong Kong since 2003. She joined the School of Biomedical Sciences, Department of Biomedical Engineering, and Institute of Tissue Engineering and Regenerative Medicine, of the Chinese University of Hong Kong since 2023.

Prof. Chan established the Tissue Engineering Laboratory with the vision to improve the quality of life in patients through bioengineering biomaterials- and stem cell-based tissues for personalized therapies. Her research interests centered around tissue engineering and regenerative medicine, natural and biomimetic biomaterials, multi-cellular organoids and tumoroids, mechano-regulation, multiphoton microfabrication and micropatterning, cell niche engineering and laser medicine.

Prof. Chan obtained her professional membership (Biomedical Engineering) and the status of Chartered Engineer and Chartered Scientist from the Institute of Materials, Minerals and Mining IMMM) since 2015. She has been a registered authorized person (AP) for advanced therapeutic products (ATPs) in Hong Kong since 2020. She has served the professional community in many areas, such as being an Associate Editor in Biomaterials since 2017, a panel member for the European Research Council since 2022, a member of the Task Force on Regulations of ATPs in Hong Kong. On knowledge exchange, together with her business partner, PhD students and Postdocs, she has co-founded a technology startup company in developing personalized tissue engineering therapies.

He is the President’s Chair in Engineering and Professor in the Chemistry, Chemical Engineering, and Biotechnology Department. He received his B.S. degree from the University of Illinois in 1996, Ph.D. from Indiana University in 2001, and post-doctoral training at the University of California (San Diego). His lab develops nanotechnology for diagnosing and treating cancer and infectious diseases. Some of his awards include NSERC E. W. R. Memorial Steacie Fellowship, Kabiller Young Investigator Award in Nanomedicine (Northwestern University), Rank Prize Fund award in Optoelectronics (England), and Dennis Gabor Award (Hungary). He is currently an Executive Editor of ACS Nano

She serves as Associate Editor of IEEE transactions on Biomedical Engineering, IEEE Journal on Biomedical Health Informatics, IEEE Transactions on Neural Systems and Rehabilitation Engineering and IEEE Journal of Translational Engineering in Health and Medicine, She is the newly elected IEEE EMBS AdCom Asia/Pacific representative. From 2020 to 2022, She was the Chair of IEEE Sensor and Systems Council China Chapter and Managing Editor of IEEE Reviews in Biomedical Engineering. She has published 2 books, 200+ scientific papers, holds 20+ granted patents, and successfully led 10+ important R&D projects. Her research focuses on biomedical unobtrusive sensor systems and health informatics, including wearable sensor systems, physiological and behavioural data sensing and analysis, multimodal approaches for health regulation, artificial intelligence for biomedical engineering, neonatal monitoring, brain activity monitoring, smart rehabilitation and sleep monitoring.

His research interests span mechanomaterials science and engineering, flexible electronics technology, sense digitalization, cyber-human interfaces and systems, and carbon-negative technology. Prof. Chen’s outstanding scientific contributions have been recognized with numerous awards, including the Singapore President’s Science Award, Singapore National Research Foundation (NRF) Investigatorship and NRF Fellowship, the Friedrich Wilhelm Bessel Research Award, Dan Maydan Prize in Nanoscience and Nanotechnology, Winner of Falling Walls, and Kabiller Young Investigator. He is an elected member of the Singapore National Academy of Science, the Academy of Engineering Singapore, and the German National Academy of Sciences Leopoldina, and an elected fellow of the Royal Society of Chemistry, the Chinese Chemical Society, and American Institute for Medical and Biological Engineering (AIMBE). Prof. Chen also serves on the editorial advisory boards of numerous esteemed international journals, including Advanced Materials, Small, and Nanoscale Horizons. Currently, he is the Editor-in-Chief of ACS Nano, a flagship journal in nanoscience and nanotechnology.

He was promoted to Associate Professor in 2008. He then moved to NIH in 2009 and became a Senior Investigator and Chief of the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH. He is currently Nasrat Muzayyin Professor in Medicine and Technology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore. Dr. Chen has published over 1000 peer-reviewed papers (H-index >190, total citations > 130,000 based on google scholar) and numerous books and book chapters. He is the founding editor of journal “Theranostics” (IF = 12.4 based 2023 Journal Citation Report). He was elected as AIMBE Fellow (2017) and SNMMI Fellow (2020), joined Advanced Materials Hall of Fame (2023), received JBN Trailblazer Award (2023), SNMMI Michael J. Welch Award (2019), ACS Bioconjugate Chemistry Lecturer Award (2016), NIH Director’s Award (2014), NIBIB Mentor Award (2012). He is also the Past President of Chinese-American Society of Nuclear Medicine and Molecular Imaging (CASNMMI), Past President of the Radiopharmaceutical Science Council (RPSC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and Past President of the Chinese American Society of Nanomedicine and Nanobiotechnology (CASNN).

He is the Executive Editor-in-Chief of Medicine in Novel Technology and Devices, Co-Executive-Editor-in-Chief of Med-X; Associate Editors and Editorial Board Members of Medical Engineering & Physics, Journal of Medical Biomechanics, SPINE, Clinical Biomechanics, Frontiers in Bioengineering and Biotechnology, Journal of Orthopaedic Translation, etc. He is an elected fellow of AIMBE and IAMBE. He received the Excellence in Clinical Science Award from the Orthopaedic Research Society of the USA and the Overseas Chinese Contribution Award of the Chinese Orthopaedic Association. Professor Cheng’s primary research focuses on musculoskeletal biomechanics, orthopaedic implants, and innovative surgical technology.

In particular, his laboratory is interested in hematologic malignancies, brain tumors, and systemic lupus erythematosus. He is also interested in cellular immune function characterization and the application to cancer immunotherapies. A microchip technology his laboratory developed for simultaneous measurement of 42 immune effector proteins in single cells, which remains the highest multiplexing to date for a single-cell protein secretion assay, has been commercialized as IsoCode and IsoLight, and currently used by >100 pharmaceutical companies and medical centers in the U.S. and around the world. Recently, his laboratory developed a novel NGS-based approach called DBiT-seq for spatial transcriptome mapping, spatial high-plex protein mapping, and spatial epigenome mapping, which may find wide-spread applications in developmental biology, cancer research, neuroscience, and immunobiology.

He received his Ph.D. at the University of California, San Diego in 2014. In 2014-2017, he was a postdoctoral fellow at the University of California, Berkeley.

He is an Associate Editor of Science Advances, npj Flexible Electronics, Biosensors and Bioelectronics, and Sensors & Diagnosis. He is a recipient of NSF Career Award, ONR Young Investigator Award, IAMBE Early Career Award, Sloan Research Fellowship, Pittcon Achievement Award, IEEE EMBS Early Career Achievement Award, IEEE Sensor Council Technical Achievement Award, MIT Technology Review 35 Innovators Under 35, Falling Walls Breakthrough of the Year 2023 in Engineering and Technology, and ACS DIC Young Investigator Award.

He is a World Economic Forum Young Scientist and a Highly Cited Researcher. His research interests include wearable biosensors, digital medicine, bioelectronics, and micro/nanorobotics.

He earned a B.A. degree summa cum laude in physics from UC Berkeley in 2001 and a Ph.D. in physics from MIT in 2007. While at MIT, he contributed to the development of quantum-enhancement techniques in the LIGO group, which received the 2017 Nobel Prize in physics for the detection of gravitational waves. In 2012, Goda joined the University of Tokyo as a professor. His research group is dedicated to developing “serendipity-enabling technologies” through extreme engineering. He has authored nearly 300 journal papers, filed over 30 patents, and launched three startups: CYBO, LucasLand, and FlyWorks. Goda has received over 30 awards and honors, including the Japan Academy Medal, JSPS Prize, SPIE Biophotonics Technology Innovator Award, and Philipp Franz von Siebold Award. Goda is a fellow of SPIE, RSC, and AAAS.

He is Director of the ARC Training Centre in Cognitive Computing for Medical Technologies and Co-Director of the Victorian Medtech Skills and Devices Hub. Prof Grayden’s main research interests are in understanding how the brain processes information, how best to present information to the brain using medical bionics, such as the bionic ear and bionic eye, and how to record information from the brain, such as for brain-machine interfaces. He is also conducting research in epileptic seizure prediction and electrical stimulation to prevent or stop epileptic seizures. Prof Grayden teaches BioDesign Innovation in collaboration with the Melbourne Business School.

He spearheads a laboratory renowned for its advancements in biomaterials and cutting-edge technologies, notably 3D/4D bioprinting. In acknowledgment of his significant contributions to the field, he has been honored with the Young Investigator Award from the Chinese Society of Stem Cell Research (CSSCR), and awarded Australia China Alumni Award for Research and Science in 2023 from Australia China Alumni Association and the Excellent Young Scientists Fund from the National Natural Science Foundation of China (NSFC). Beyond research, he lends his expertise to the editorial boards of esteemed journals, such as Biofabrication, Bioactive Materials, Cell Proliferation, and BMEMat.

He received his BSc from Chemical Engineering Department at National Taiwan University in 1990 and earned his MSCEP and Ph.D. in 1994 and 1997, respectively, from Chemical Engineering Department at the Massachusetts Institute of Technology (MIT). Utilizing chemical engineering and molecular engineering principles, his group is interested in nucleic acid engineering and DNA self-assembly for analyte sensing and diagnostic applications for point of care testing. His group is also interested in developing organic electrochemical transistors and flexible green bioelectronic and materials for non-invasive and wearable sensing/monitoring biomedical applications. In recent years, his group has garnered interests in developing nature-derived biomaterials for chronic wound care. He is the Founding President of Asia Pacific Biomedical Engineering Consortium (APBEC) that promotes and fosters collaborative research and education in the fields of biomedical engineering and translational medicine.

 He is also the Chief Executive Officer of Opticho Inc. He was the recipients of the 2022 Korean Presidential Award from Ministry of SMEs and Startups, the 2017 IEEE EMBS Early Career Achievement Award, etc. He has published 233 peer-reviewed journal articles (Nature portfolio journals, PNAS,  etc). His Google Scholar h-index and citations have reached 71 and over 18,300, respectively. He is also elected as a member of the National Academy of Engineering of Korea (NAEK) and Young Korean Academy of Science and Technology (Y-KAST). He is a Fellow of the IEEE, SPIE, and OPTICA.

He finished his postdoc with Dr. Michael M. Gottesman, member of NAS and Deputy Director of NIH, for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS, NIH. Dr. Liang currently is a principal investigator at Center for Excellence in Nanoscience, Chinese Academy of Sciences. As previous president of Chinese Association of Nanobiology, he is the Member of Academia Europaea (2023) and the elected Fellow of American Institute for Medical and Biological Engineering (AIMBE, 2020) and Faculty Member of F1000 Research (Pharmacology & Drug Delivery, 2012) and Hall of Fame (Advanced Materials, 2023). Dr. Liang has successfully developed “Injectable Nanomicelle Powder with Irinotecan” approved with CFDA and transferred NDA to pharmaceutical industry for clinical trials.

His group has published over 300 peer-reviewed articles, H-index > 108. His research interests are in elucidating mechanisms to improve drugability and nanomedicinal bioavailability by nanotechnology in vitro and in vivo, and novel strategies to increase therapeutic efficiency on cancers and infective diseases. Developing drug delivery strategies for prevention/circumvent of clinical adaptive treatment tolerance (ATT) are current programs ongoing in Professor Liang’s lab based on understanding of basic physio-chemical and biological processes of nanomedicine.

Since 1996, I have been leading independent research groups, initially at NUMI, NUS (National University of Singapore) from 1996 to 2001, and subsequently at various ASTAR research institutes from 2002 to 2024. Throughout my career, my research has centered on elucidating the molecular and cellular mechanisms underlying diseases and developing therapies. Notably, my laboratory discovered MSC exosomes in 2008.

Through rigorous investigation of MSC exosome biology, my collaborators and I have achieved several significant milestones, including pioneering the efficacious use of MSC exosomes against various diseases and injuries, developing scalable exosome production technologies, identifying key regulatory metrics in exosome drug release criteria, and elucidating disease-specific mechanisms of action of MSC exosomes. In recognition of this work, I have been named a Clarivate Highly Cited Researcher for the years 2021, 2022, and 2023 and 2023 ISEV Special Achievement Award (Stem Cell EV).

As an inventor, I hold a portfolio of 12 families of MSC exosome intellectual property, comprising 97 granted patents and 17 pending applications. Additionally, I have founded three start-ups. One of these start-ups completed a phase 1 clinical trial in May 2022, testing topically applied MSC exosomes in psoriasis.

I currently serve as an associate editor at Cytotherapy and JEV, and have held leadership positions in organizations such as ISEV (board member), ISCT (Co-chair, Exosome Committee), and SOCRATES (president).

She is also the director of CUHK(SZ)-BoyaLife Joint Laboratory for Regenerative Medicine Engineering. Her career is alternating between academia and industry. She is focusing on the development of integrated biosensing devices to precisely diagnose, manage, and prevent chronic diseases (diabetes, Parkinson’s disease, osteoarthritis, et al). Her team has developed various assays for quantifying inflammation by detection of inflammatory factors (such as cytokines) from point-of-care testing to in vivo monitoring. She was awarded a prestigious ARC Future Fellowship in 2016 and won the Georgina Sweet Award for Women in Quantitative Biomedical Science in 2020. Additionally, she has extensive experience in biomedical device development in industry (such as AstraZeneca). She used to work at AgaMatrix Inc. as the R&D Manager, China and is the co-founder of Bio-Sens Tech Pty Ltd. 

He is Executive Dean of Institute for AI Industry Research (AIR) and Associate Dean of the Department of Computer Science and Technology. His research interests include artificial intelligence, natural language processing, and AI for Science.

He received COLING/ACL 2006 Meritorious Asian NLP Paper Award, ACL 2017 Outstanding Paper Award, ACL 2023 Outstanding Paper Award, and ICLR 2023 Outstanding Paper Award Honorable Mention. He served as Executive Committee Member of Asia-Pacific Chapter of ACL, Editorial Board Member of Computational Linguistics, and Associate Editor of ACM TALLIP.

After his appointment in industry at the Institute of Electrical Engineering “Koncar,“ he joined the Electronic Measurement and Biomedical Engineering Group at the University of Zagreb Faculty of Electrical Engineering and Computing. He is full professor teaching several courses in Electronic Instrumentation and Biomedical Engineering at undergraduate, graduate and at postgraduate studies.

His scientific and professional interest is in fields of electronic and biomedical instrumentation and digital health, in particular in cardiac potentials analysis and pacing, in research of new methods for drug delivery based on electropermeabilisation and recently in research of personalized intelligent mobile health systems. He is author or co-author of numerous journal and conference papers, several textbooks and book chapters. R. Magjarevic is elected for President of the International Federation for Medical and Biological Engineering (IFMBE) from 2022 to 2025.

She was promoted to Associate Professor in 2011 and she is currently Head of the Department of Pharmacy & Pharmaceutical Sciences, NUS. Her main research interests include production, characterization and evaluation of cell-derived nanovesicles (CDNs) as novel biocompatible and targeted drug delivery systems of bioactive molecules such as Pt-based anticancer complexes.

She is the main inventor for several US patents, provisional patents and invention disclosures. Her research has attracted industrial collaborations with pharmaceutical companies such as Pfizer (USA), P&G, Leung Kai Fook Medical and MDImune (South Korea). For the work performed by her BioNano-technology (BNT) group, she received both university and international awards.

From 2020 to September 2023, he worked as Innovation Manager for the World Health Organization (WHO), Emergency program (WHE) Infection Prevention and Control (IPC) unit.

Since September 2013, he has been professor of biomedical engineering at the University of Warwick, UK, where he still co-direct the Applied Biomedical Signal Processing and Intelligent eHealth Lab (ABSPIE). From 2010 to 2013, he worked with the University of Sheffield and the University of Nottingham, in the UK.

Prof Pecchia is a leading partner in several European research projects focusing on IA and IoT for healthcare remote monitoring (e.g., Large Scale Pilot Manager of the GATEKEEPEP project) and the use of AI and robots to improve hospital efficiency and safety (e.g., Pilot Manager of the ODIN project). Since he moved in Italy in 2022, he was involved in National projects on medical robots (Fit4MedRob) and on the use of AI for rare diseases (heart, eye and cancer).

Prof Pecchia authored more than 200 peer-reviewed papers on journals, books and conferences in the fields of Artificial Intelligence, medical devices, biomedical signal processing, Health Technology Assessment (HTA), Internet of Things and machine learning applied to active and healthy ageing and management of chronic diseases.

Prof Pecchia is the Secretary General of the International Federation of Medical and Biological Engineering (IFMBE), and NGO in official relations with the WHO, and the Past President of the European scientific society of biomedical engineering (EAMBES). In the past, he served the international community of biomedical engineers as Secretary General (2018-22) of the International scientific society of medical physics and biomedical engineering (IUPESM), Treasurer (2018-25) of the IFMBE Clinical Engineering Division, and IFMBE Healthcare Technology Assessment Division Chair (2015-18) and Treasurer (2012-15).

• Laboratory: https://www.unicampus.it/en/info/intelligent-technologies-for-health-and-well-being-sustainable-design-management-and-evaluation
• Staff webpage (Warwick): https://www.unicampus.it/it/persone/4468
• Linkedin: https://www.linkedin.com/in/pecchia/

She received her B.S. in Chemical Engineering from Northwestern University in 2002 and went on to obtain her MS and PhD in Chemical Engineering from the University of California, Irvine in 2007. She was then an NIH Kirschstein post-doctoral fellow in the Biological Engineering department at MIT before starting her academic appointment at the University of Massachusetts Amherst in 2011, before moving to Tufts University in 2024. Shelly leads an interdisciplinary group of engineers and molecular cell biologists seeking to create and apply novel biomaterials platforms toward new solutions to grand challenges in human health. Her lab’s unique approach is using our engineering expertise to build simplified models of human tissue with synthetic biomaterials. They use these systems to understand 1) the physical relationship between metastatic breast cancer cells and the tissues to which they spread, 2) the role of the extracellular matrix and its dynamics in drug resistance, and 3) how to create bioinspired, mechanically dynamic and activatable biomaterials. Among other honors for her work, Shelly was a 2013 Pew Biomedical Scholar, received a New Innovator Award from the NIH, and she was awarded a CAREER grant from the NSF. Shelly is a fellow of the Biomedical Engineering Society and a fellow of the American Institute for Medical and Biological Engineering. Shelly is passionate about graduate student training and diversifying the academy. She was awarded an Outstanding Teaching Award from the College of Engineering at UMass in 2018, has led an REU Site, co-directed a Biotechnology (BTP) NIH T32 training program, and was lead PI of a PREP program at UMass, which hosts students from historically excluded groups for a 1-year research-intensive program to help prepare them for graduate school. She also runs an NSF-funded program called Engineering the Cell, which brings female high school students to her lab for 5 weeks every summer. Outside of her work, Shelly is an avid cyclist, enjoys board games, travel, and is a retired ultimate frisbee player.

With an h-index of 113 and over 35,000 citations, he is recognized as one of the world’s most influential researchers by Web of Science and has earned prestigious honors, including the Singapore National Research Foundation (NRF) Investigatorship and Biomaterials Science Lectureship Award. He serves as the editor for ACS Applied Polymer Materials, Biomaterials Research, and Smart Molecules, as well as the editorial advisory braod member for more than 18 top journals, including Chemical Society Reviews, Advanced Functional Materials, Biomaterials, Small, and Bioconjugated Chemistry.

His research interests include emulsion, biomicrofluidics, biomedical engineering, and soft matter. Prof. Shum is highly recognized for his pioneering contributions and received numerous international scientific honors, including but not limited to the Guanghua Engineering Science Prize (2024), Research Grants Council of Hong Kong (RGC) Senior Research Fellowship (2024), Hong Kong Engineering Science and Technology Award (2022), and Croucher Senior Research Fellowship (2020). He was selected as Fellow of Hong Kong Institution of Engineers in 2023, Member of Global Young Academy in 2021, Founding Member (2018) and President (2021) of Hong Kong Young Academy of Sciences, and Fellow of Royal Society of Chemistry (RSC) in 2017. He serves as an Associate Editor for Biomicrofluidics (American Institute of Physics), Editorial Board Member for Microsystems and Nanoengineering (Springer Nature) and Scientific Reports (Springer Nature), and Editorial Advisory Board Member for Lab-on-a-Chip (RSC).

Xinyi’s research focus on harnessing biomaterial, regenerative stem-cell, and nucleic acid technologies for the treatment of age-related retinal degenerative disease. Her work has been published in, inter alia, Nature Biomedical Engineering, Nature Communications, Lancet Global Health, PNAS, and Advanced Materials. With a career total of over SGD25 million in competitive research grants, Xinyi is also the recipient of multiple global and national awards, including the Asia-Pacific Academy of Ophthalmology’s Young Ophthalmologist Award (2019), the Asia-Pacific Vitreo-Retinal Society Leadership Development Program Gold Award (2020), Ten Outstanding Young Persons of Singapore Award (for Medical Innovation, 2021), the Susan Lim Outstanding Stem Cell Young Investigator Award (2022) and National Medical Research Council Clinician Scientist Award (2022). In 2022, she was accepted into the prestigious international membership of The Macular Society.

Passionate about clinical translation of research, Xinyi holds several patents and co-founded an ISO 13485 (Medical Device Quality System) accredited spin-off company, Vitreogel Innovations, focussed on developing next-gen vitreous substitutes. Beyond research, Xinyi is committed to talent development and has mentored numerous clinician-scientists as the Deputy Director of the Clinician-Scientist Academy (NUHS).

He was awarded the National Research Foundation Fellowship in 2017. He obtained his PhD at Stanford University, and was a 2014 Singapore-Stanford Biodesign Global Innovation Postdoctoral Fellow. He won the MIT TR35 Innovator (Global) award in 2015 and listed as World Economic Forum’s Young Scientist of the year in 2019. His research team won the International Winner of the James Dyson Foundation Prize in 2021 for their work on healthcare sensors. This was the 1st time a Singapore team won as the international winner in the award’s 17-year history.

He leads the Sensors.AI Labs that research and translate technologies at the cutting edge of materials science, mechanics, electronics and biology. His current focus is on developing new skin-like electronic materials and systems that have tremendous potential to advance robotics and healthcare technologies in an increasingly Artificial Intelligence (AI) era. His inventions can help to tackle challenging needs in health, robotics and AI.

He has translated technologies for real-world impact through entrepreneurial pursuits. He has co-founded two medical technology companies Privi Medical and Hannah Life Technologies in Singapore. Privi Medical was successfully acquired in 2021 and Hannah Life Technologies grew rapidly and reached double-digit percentage monthly revenue growth across international markets such as the US, UK and Singapore within 12 months of product launch.

He has been featured by multiple top international news agencies including CNN International as one of their Tomorrow’s Hero series, by Channel News Asia International in the ASEAN’s Next Generation Leaders documentary and by BBC World Service Radio and National Geographic TV.

She obtained her B.Eng in Chemical Engineering and Ph.D in Bioengineering from the National University of Singapore in 2001 and 2008, respectively. She did her post-doctoral training at the Massachusetts Institute of Technology and A*STAR Institute of Bioengineering and Nanotechnology. Before joining QUT in 2019, she was an Assistant Professor at the Department of Biomedical Engineering, National University of Singapore.

Yi-Chin leads the Micro Tissue Engineering Lab (https://microtelab.com/). Her major scientific contribution is in advancing microfluidic tissue models for applications in drug testing and experimental biology. To date, she has produced 70 peer-reviewed publications (h-index = 30, 3900 citations), eight patent applications, and over 100 conference presentations. Her works on alternative animal technologies have won accolades, such as the Lab on a Chip & Dolomite Pioneers in Miniaturization Lectureship Award (2022) and Global 3R Award (2019). Yi-Chin has taken up various leadership roles in the national and international scientific community. She serves in the Australian Research Council College of Experts, the Scientific Advisory Committee of Lab on a Chip (2022) and AIP Biomicrofluidics (2022), and the editorial board of Springer-Nature Microsystems & Nanotechnology (2023). She also contributes actively to the organization of the MicroTAS conference series, including the Poster Award Committee (2018-2019) and the Executive Technical Program Committee (ETPC) in 2021.

She is actively involved in the development of various novel medical devices, such as biomimetic minimally biodegradable nucleus pulposus scaffold, nanofibrous tissue engineering scaffold with adjustable mechanical and electrical properties. Lizhen has generated over 100 peer-reviewed journal papers including 80 journal articles, 20 conference proceedings and book chapters. She is the Chair of World Association for Chinese Biomedical Engineers (WACBE) Young Committee, Associate Editor of Computer Methods in Biomechanics and Biomedical Engineering (CMBBE).

He received his Ph.D. degree in Materials Science and Engineering from the Georgia Institute of Technology in 2014, and his Bachelor’s degree from Tsinghua University in 2009. From 2015 to 2018, he was a postdoctoral fellow in Chemical Engineering at Stanford University. He has published over 80 papers in numerous high-impact journals, including Science, Nature, Nature Materials, Nature Electronics, etc. As of September 2024, his research has been cited more than 27,400 times and he has an H-index of 65. He was recognized as a Highly Cited Researcher by Clarivate Analytics from 2020 to 2023, and was awarded the NIH Director’s New Innovator Award, NSF CAREER Award, Office of Naval Research (ONR) Young Investigator Award, MIT Technology Review 35 Innovators Under 35 (TR35 Global List), Chan Zuckerberg Biohub Investigator Award, etc.

He earned his B.S. degree in Chemistry from Peking University and his Ph.D. in Materials Science and Engineering from the Georgia Institute of Technology. Subsequently, he pursued postdoctoral studies at the Materials Research Laboratory at the University of Illinois at Urbana-Champaign. His research group is interested in developing new materials and fabrication methods for soft electronics, with a particular focus on wearable ultrasound technology. His research has been presented to the United States Congress as a testimony to the importance and impact of funding from the National Institutes of Health. He has received numerous honors, including the Sloan Fellowship, IEEE EMBS Technical Achievement Award, ETH Zürich Materials Research Prize for Young Investigators, MRS Outstanding Early Career Investigator Award, and a finalist of the Blavatnik National Awards for Young Scientists. He is an AIMBE Fellow.

He is currently an Associate Professor in the Department of Medicine at Harvard Medical School and Associate Bioengineer in the Division of Engineering in Medicine at the Brigham and Women’s Hospital. Dr. Zhang is directing the Laboratory of Engineered Living Systems (www.shrikezhang.com), where the research is focused on innovating medical engineering technologies, including 3D bioprinting, organs-on-chips, microfluidics, and bioanalysis, to recreate functional tissues and their biomimetic models, for applications in regenerative medicine and personalized medicine.

He is an author of >330 peer-reviewed publications citations >35,000, h-index>93). His scientific contributions have been recognized by >50 international, national, and regional awards.

Before joining CityU, he was a Provost’s Chair Professor and had over 20 years of working experience in the Department of Biomedical Engineering at the National University of Singapore (NUS). Prof Zhang’s research interests include functional nanomaterials, microfabricated devices and wearable/implantable technologies for healthcare applications. He has authored over 350 research articles in journals such as Nature Medicine, Nature Biomedical Engineering and PNAS, delivered more than 70 plenary/keynote/invited talks in international conferences, and received many awards such as Humboldt Research Award and IES Prestigious Engineering Achievement Award.

He has recently been awarded the prestigious Global STEM Professorship by the Hong Kong SAR. He is a Clarivate highly cited researcher, an elected Fellow of Singapore Academy of Engineering and Royal Society of Chemistry. He is also a founder of four start-up companies to commercialize his technologies.

In one strand of work, rapid, zero-cost “origami paper” diagnostics are being trialled in rural Uganda. These species-specific DNA sensors are used to identify the cause of infectious disease and inform treatment “in the field”. Further examples include bathroom diagnostics, sold as products on the high street (e.g. Boots the Chemist).

He was elected as a Fellow of the Royal Academy of Engineering (UK’s national academy of engineering) as well as a Fellow of the Royal Society of Edinburgh (Scotland’s national academy of arts, humanities and sciences).

He obtained his Ph.D. from the Georgia Institute of Technology in 2016, followed by postdoctoral studies at Stanford University. His current research focuses on soft matter innovation for novel bioelectronics. With a current h-index of 108, he was identified to be one of the world’s most influential researchers in the field of materials science in Web of Science.

He has published 2 books, 3 book chapters, 300 journal articles, and 200 of them are as corresponding authors in Chemical Reviews (2), Chemical Society Reviews (2), Nature Reviews Bioengineering, Nature Materials (2), Nature Electronics (7), Nature Biomedical Engineering, Nature Communications (6), Science Advances(3), Joule (3), Matter (14), Advanced Materials (16), ACS Nano (18), and many others. He also filed 17 US patents and licensed 1. These works were highlighted by Nature and Science 7 times and worldwide media over 1,200 times in total, including NBC, CNN, NPR, ABC, The Wall Street Journal, Scientific American, and Science Daily.

As the Assistant Group Chief Technology Officer for the National University Health System, Dr Gao is involved in the research and development of immersive technology and its application in clinical care and education, and digital-twin projects. He works extensively with Mixed Reality (MR) technology, utilising MR devices to deliver cutting edge capabilities to clinicians including 3D holographic imaging, real-time computer-vision based imaged analysis, and multisource data integration. He is also responsible for the integration and implementation of 5G wireless technology for hospital infrastructure development and building of secured high-speed integrated data networks. He also serves as the Vice-Chairman of the international Holomedicine Association.

As a senior postdoctoral associate in the Singapore-MIT Alliance for Research and Technology, she developed microfluidic-based tools for rare cell detection.

Now Dr. Khoo’s research group is focusing on detecting, prognosis, and characterization of disease heterogeneity using multidisciplinary techniques, including the design and utilization of microfluidic devices for personalized cancer management and evaluation. Dr. Khoo has authored more than 63 articles in top journals such as Energy & Environmental Science, Chemical Engineering Journal, Small, Biosensors and Bioelectronics, Science Advances, Nature Protocols, etc., and held at least 11 patents pending or granted.

Dr. Khoo was awarded the Young Investigator national grant award by the National Medical Research Council and the Young Investigator award to support projects in disease detection via the Interstellar Initiative, funded by the Japan Agency for Medical Research and Development (AMED) and the New York Academy of Sciences. Dr Khoo’s team was award 2x Silver at the recent The International Exhibition of Inventions of Geneva (“IEIG”). She is also the recipient of Innovators under 35 (Asia; MIT Technology Review) for her work on microfluidic devices with direct clinical relevance.

Apart from research, Dr Khoo and her team are also actively seeking opportunities to encourage young people to enter the field of biomedical engineering through the implementation of the Gifted and Talented Program schemes organized by the Education Bureau, and received the CENG Outstanding Teaching Award for her efforts.

He was awarded presidential young professorship and selected as one of the “Innovators Under 35” (Asia Pacific, MIT review). His research interests include tissue-mimicking brain-machine interface and wearable electronics.

She discovered the “Golden Window” for deep tissue imaging and developed bioorthogonal metabolic imaging platforms that combine deuterium probing and stimulated Raman scattering (DO-SRS using heavy water and STRIDE with D-glucose) for visualizing metabolic activities in situ. The Shi group transformed SRS into a super resolution microscopy with chemical selectivity by developing Adam optimization-based Pointillism Deconvolution (A-PoD) methods.

Dr. Shi holds six awarded patents. She won the Blavatnik Regional Award for Young Scientist in 2018; the Hellman Fellowship Award 2021; the “Rising Star Award” by LaserFocusWorld, and the “Rising Star Award” by Nature Light Science & Applications in 2021; the “Advancing Bioimaging Scialog Fellow” by RCSA and the Chan Zuckerberg Initiative in 2021, 2022, and 2023; and the Sloan Research Fellow Award in Chemistry 2023.

Dr. Shi has been mentoring graduate and undergraduate students to help them achieve excellence in academic work and become successful engineers and scientists. She plans to continue making additional contributions by enhancing more participation of underrepresented groups from the UC San Diego communities. She has been teaching core undergraduate and graduate courses in the Shu Chien-Gene Lay Department of Bioengineering at the UC San Diego Jacobs School of Engineering.

Andy next received his postdoctoral training at Stanford University before heading to Imperial College London as an 1851 Royal Commission Brunel Research Fellow. He is currently a Presidential Young Professor in NUS.

Andy is a recipient of international awards including the Interstellar Initiative Early-Career Faculty Award, Christopher Hewitt Outstanding Young Investigator Award, Terasaki Young Innovator Award. He is listed as a 2019 Forbes 30 Under 30 (US/Canada, Science), 2020 World Economic Forum Young Scientist and 2022/3 Top 2% Scientist in the World by Stanford University.

His current research interests focus on computational imaging and system biology, with a particular emphasis on developing mesoscale optical setups for observing large-scale biological dynamics in vivo. He has proposed a series of new microscopic imaging framework including camera-array-based gigapixel mesoscale microscopy, scanning light field microscopy, digital adaptive optics, and two-photon synthetic aperture microscopy to overcome the barriers of intravital imaging, with orders of magnitude improvement in spatiotemporal resolution, imaging data throughput, and orders of magnitude reduction in phototoxicity for long-term observations.

His work has been published in more than 40 journal papers such as Nature, Cell, Nature Methods, etc, opening up a new horizon for the study of large-scale intercellular interactions in mammals. He has served as the Associate Editor of PhotoniX and IEEE TCSVT, and Guest Editor of Light: Science & Applications.

Dr Yu is the recipient of RGC Research Fellow, Innovators under 35 China (MIT Technology Review), NSFC Excellent Young Scientist Grant (Hong Kong & Macao), New Innovator of IEEE NanoMed, MINE Young Scientist Award, Gold Medal in the Inventions Geneva, CityU Outstanding Research Award, Stanford’s top 2% most highly cited scientists etc. Xinge Yu’s research group is focusing on skin-integrated electronics and systems for VR and biomedical applications.

Dr. Yu is the Associate Editor and Editor Boards over 10 journals, such as Microsystem & NanoEngineering, Bio-Design and Manufacturing, IEEE Open Journal of Nanotechnology, etc. He has published 160 papers in Nature, Nature Materials, Nature Biomedical Engineering, Nature Machine Intelligence, Nature Communications, Science Advances etc., and 40 patents filed/granted.

After completing his Residency training in 2019, he obtained his Fellowship of the Royal College of Surgeons of Edinburgh and was accredited as a Specialist in General Surgery by the Specialist Accreditation Board. Dr Gao has a sub-specialty interest in hepatobiliary, pancreatic, and liver transplant surgery and joined the Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery in 2020. He is currently the Deputy Undergraduate Medical Education Director in the Department of Surgery, National University Hospital.

Apart from his clinical work, Dr Gao is deeply involved in undergraduate medical education at the Yong Loo Lin School of Medicine, serving as a Clinical Lecturer and participating actively in curriculum planning and review. He is a member of the Systems Block Workgroup (Gastrointestinal and Metabolism) committee and Medical Education Technology Enterprise (METE) committee.

Dr Gao also has special interests in Health Informatics, Artificial Intelligence, Data Transformation, and Medical Technology, taking the lead in NGEMR change for the Department of Surgery, and spearheading various other projects including the development of Holomedicine, Mixed Virtual Reality devices, and Applications for medical education and clinical medicine.

He subsequently enrolled in the Harvard-MIT Division of Health Sciences and Technology and received his Ph.D. in Medical Engineering and Medical Physics from MIT in 2017. In September 2017, Dr. Chen joined the Radiological Sciences Laboratory at Stanford University as a postdoctoral researcher and since August 2021 has been an assistant professor and Fubon Bacui Scholar at National Taiwan University.

His current research focuses on the development and integration of artificial intelligence and multimodal medical image processing techniques for the improved quantification of positron emission tomography images. He was a recipient of the Cornelius G. Dyke Memorial Award from the American Society of Neuroradiology.

He earned his B.Sc. degree in Chemistry from Peking University, followed by a Ph.D. in Chemistry from Harvard University, advised by Charles Lieber. Dr. Dai further pursued postdoctoral research at Harvard University, Tufts University, and MIT. His research focuses on the seamless integration of nanoelectronics and living tissues, particularly emphasizing on cyborg tissues, biostealthy neural electrodes, and multi-modal brain-machine interfaces.

Dr. Dai has authored over 20 articles in journals such as Nature Nanotechnology, Nature Materials, and PNAS. He has secured over 10 grants in the past two years from organizations including MoST, NSFC, Beijing MSTC, Tsinghua University, and National Laboratories. Dr. Dai has received honors such as the Beijing Nova Program, Quisuo Program for Distinguished Young Scholars and serves as Associate Editor for Nano TransMed since 2021.

She was a postdoctoral researcher at Stanford University and received a B.S. degree from Georgia Tech and an M.S. and Ph.D. from Stanford University. Her research includes soft actuators, sensors, medical robotics, haptics, and biomimetics.

Prof. Han’s awards include the 2022 Best RA-L Paper Award, the 2022 ICROS Outstanding Early Career Researcher Award, and the ICRA 2021 Best Poster Presentation. She was also recognized as one of the 50 Women in Robotics in 2023 and a Rising Star in Mechanical Engineering in 2019.

His expertise lies in protein engineering, where he designs and optimizes proteins by integrating high-throughput experiments with computational approaches. He received his Ph.D. from the University of Tokyo in 2015 and worked as a researcher at Toray Industries, Inc. from 2015 to 2020 before joining his current position at the University of Tokyo in 2020. In this research, the aim is to advance protein design through innovative techniques that combine cutting-edge experimental methods with advanced computational science. The goal is to contribute to the development of new technologies and applications in the field of bioengineering.

Prior to joining HKUST, she received her PhD from UC Berkeley in 2020 and did postdoc training at Stanford. As a leading author, she has published several pioneer works on wearable sensing technology in major journals including Nature, Nature Communications, Advanced Materials, and ACS Sensors. She was recognized as an innovator in TR35 Asia Pacific 2021 awarded by MIT Technology Review.

He is also an assistant professor by courtesy in Electrical and Computer Engineering and a PI in the Institute for Health Innovation and Technology and the N.1 Institute for Health, NUS. He received his PhD in MSE from Georgia Tech and carried out postdoctoral research in the Querrey Simpson Institute for Bioelectronics at Northwestern University.

His research focuses on developing wireless wearables and intelligent robots for energy harvesting, biosensing and therapeutic applications, leveraging bioelectronics, materials science, and advanced manufacturing to create solutions for sustainable living and environment.